Bioavailability of oral ciprofloxacin in early postsurgical patients

Archives of Surgery

Volumn 133, Issue 11, 1998, Pages 1221-1225

  Hackam, David J ^a   Christou, Nicolas ^b   Khaliq, Yasmin ^c   Duffy, Dianne R ^a   Vaughan, David ^d   Marshall, John C ^a   Rotstein, Ori D ^a,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Bayer Inc   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; OBESITY; ORAL DRUG ADMINISTRATION; PERITONITIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 0031737433     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.133.11.1221     Document Type: Article

References (20)

1. Bohnen JM, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. Arch Surg. 1992;127:83-89.
2. Holzheimer RG, Haupt W, Thiede A, et al. The challenge of postoperative infections: does the surgeon make a difference? Infect Control Hosp Epidemiol. 1997; 18:449-456.
3. Lettieri JT, Rogge MC, Kaiser L, et al. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992; 36:993-996.
4. Fry DE. The importance of antibiotic pharmacokinetics in critical illness. Am J Surg. 1996;172:20-25.
5. Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin Ther. 1992;14:348-375.
6. Bauerfeind A. Comparative in vitro activities of the new quinolone, Bay y3118, and ciprofoxacin, sparfloxacin, tosofloxacin, Cl-960, and Cl-990. Antimicrob Agents Chemother. 1993;31:505-522.
7. Thadepalli H, Bansal MB, Rao B, et al. Ciprofloxacin: in vitro, experimental, and clinical evaluation. Rev Infect Dis. 1988;10:505-515.
8. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infection. Ann Surg. 1996;223:303-315.
9. Ohman NC, Hau T. Prognostic indices in peritonitis. Hepatogastroenterology. 1997; 44:937-946.
10. Nix DE, DeVito JM, Schentag JJ. Lipid Chromatographic determination of ciprofloxacin in serum and urine. Clin Chem. 1985;31:684-686.
11. Nix DE, Goodwin D, Peloquin CA, et al. Antibiotic tissue penetration and its relevance models of tissue penetration and their meaning. Antimicrob Agents Chemother. 1991;35:1947-1959.
12. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073-1081.
13. Bohnen JM. Duration of antibiotic treatment in surgical infections of the abdomen: postoperative peritonitis. Eur J Surg. 1996;576:50-52.
14. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery. 1995;118:716-721.
15. Sanders J. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis. 1988;10:528-543.
16. Peacock JE, Pegram PS, Weber SF, et al. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med. 1989;87:185-190.
17. Hoffken G, Lode H, Prinzing C, et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985;27:375-379.
18. Cohn SM, Cohn KA, Rafferty MJ, et al. Enteric absorption of ciprofloxacin during the immediate postoperative period. J Antimicrob Chemother. 1995;36:717-721.
19. Barriere SL, Ely E, Kapusnik JE, et al. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother. 1985;16:49-59.
20. Wolfson JS, Swartz MN. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med. 1985;312:968-975.